Moderna COVID-19 vaccine gets EU regulator endorsement for teens
Reuters
Published Jul 23, 2021 11:22AM ET
By Pushkala Aripaka
(Reuters) -Moderna's COVID-19 vaccine could become the second shot okayed for adolescent use in the European Union after regulators on Friday recommended approving it for 12- to 17-year-olds ahead of U.S. authorities.
Use of the vaccine, Spikevax, will be the same in adolescents as in people over 18, the European Medicines Agency (EMA) said, adding the shot produced a comparable antibody response to that seen in 18- to 25-year-olds.
Vaccinating children has been considered important for reaching herd immunity and in light of the highly contagious Delta variant. Moderna (NASDAQ:MRNA) in May said its vaccine was found to be safe and effective in teenagers.
The EMA said the two-dose vaccine is given four weeks apart, and its human medicines committee's recommendation was based on a study of 3,732 participants.
Most children with COVID-19 develop only mild symptoms or none. Yet children remain at risk of becoming seriously ill and can spread the virus. Pfizer (NYSE:PFE) and German partner BioNTech's vaccine was approved for teen use in May.
The regulator said common side effects in teenagers after vaccination with Spikevax were similar to those seen in older people. But due to a smaller study size, the trial could not detect new uncommon side effects or estimate the risk of known ones such as myocarditis and pericarditis.
"The overall safety profile of Spikevax determined in adults was confirmed in the adolescent study; the CHMP (Committee for Medicinal Products for Human Use) therefore considered that the benefits of Spikevax in children aged 12 to 17 outweigh the risks," the EMA said https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu.
Heart inflammation such as myocarditis and pericarditis have been listed by the EMA as a possible, but rare side effect from use of mRNA vaccines such as Moderna's and Pfizer's in adults.
Spikevax is already being used in the European Union for people over 18, and in the United States and Canada. The company has also sought authorisation in the United States and Canada for use in adolescents.
Get The News You Want
Moderna said on Friday it had submitted data to authorities around the world and expects authorisations for adolescents in the coming weeks.
Formal approval from the European Commission would be needed to start rolling out the vaccine for teenagers in Europe. The executive body typically follows EMA recommendations.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.